Signs your MS may be progressing — when to worry and what to do

May 27, 2026

How to recognise that multiple sclerosis is progressing from RRMS to SPMS or from stable to active disease. A guide to red-flag symptoms, EDSS changes, MRI activity, and when to talk to your neurologist.

What "progression" means in multiple sclerosis

I keep returning to this subject because a useful answer should be precise without losing sight of everyday life. In multiple sclerosis, progression means that the disease is gradually worsening over time — independent of individual relapses. Most people with MS are first diagnosed with relapsing-remitting MS (RRMS), where symptoms flare up during relapses and then partially or fully improve. Over time, however, many patients transition to secondary progressive MS (SPMS), where disability worsens steadily even between relapses. A smaller group starts with primary progressive MS (PPMS), where decline is continuous from the beginning. Recognising the signs of progression early matters because today's treatments can slow it down — but only if action is taken in time (Lublin 2014, MS Trust).

Early physical warning signs that MS may be progressing

The body often sends signals before a formal diagnosis of progression is made. Pay attention to the following:

1) Worsening walking and balance. If your gait becomes unsteadier, you trip more often, need to hold walls, or your walking distance shrinks over months — this is one of the earliest and most reliable signs of progression. The distance you can walk without stopping is a sensitive indicator of spinal cord involvement (EDSS 4.0–6.0 range).

2) Increased spasticity and stiffness. Muscle tightness that was occasional becomes daily. Calves, hamstrings and hip flexors feel constantly stiff. Stretching and medications that used to help are now less effective. New spasms appear at night.

3) New or worsening weakness in the same limb. After a relapse, some weakness often remains. But if that same arm or leg becomes progressively weaker over 6–12 months — without a new relapse — this suggests gradual axonal loss, not just residual damage.

4) Bladder and bowel changes. More frequent urination, stronger urgency, incomplete emptying, or new incontinence can signal progression of spinal lesions affecting the autonomic pathways. Constipation that was manageable now requires daily laxatives.

5) Increased fatigue that does not improve with rest. A step-change in fatigue — where even good sleep, pacing and cooling no longer restore energy — can indicate that the brain is working harder to compensate for accumulating damage.

6) Vision decline that does not recover. After optic neuritis, vision usually improves. If visual acuity, colour perception or contrast sensitivity keeps declining without a new acute episode, this points to progressive optic nerve atrophy.

7) Numbness or tingling that spreads or becomes permanent. Sensory symptoms that were transient now persist for months. New areas of numbness appear without an obvious relapse.

Cognitive and functional warning signs

Progression is not only physical. Cognitive and day-to-day functional changes are equally important:

1) Brain fog becomes more frequent. Forgetting appointments, losing track of conversations, struggling to find words — more than before. This is often called "cognitive fatigue" and reflects progression in frontal and temporal white-matter pathways.

2) Processing speed slows down. Tasks that used to take 10 minutes now take 30. Reading comprehension drops. You need more time to respond in conversations.

3) Mood changes — depression or emotional lability. Sudden crying, irritability, or apathy can reflect frontal-lobe involvement. Depression is more common in progressive phases and can itself accelerate disability perception.

4) Less ability to multitask. You can no longer cook and hold a conversation. Background noise becomes overwhelming. This reflects reduced cognitive reserve as lesion burden grows.

5) Reduced independence in daily activities. You need help with dressing, cooking, showering or managing medications — tasks you did alone a year ago.

What MRI changes tell you

MRI is the most objective tool for tracking progression. Here is what your neurologist looks for:

New T2 lesions — especially if they appear between annual scans despite DMT therapy. Even "asymptomatic" new lesions matter; they indicate ongoing inflammatory activity.

T1 hypointense lesions ("black holes") — these represent areas of permanent tissue destruction (axonal loss). An increasing number of black holes is a strong predictor of future disability.

Brain atrophy — shrinkage of grey matter (cortex) and white matter over time. Whole-brain atrophy rates above 0.5–1% per year in MS are considered accelerated. Atrophy correlates strongly with cognitive decline and physical disability.

Spinal cord atrophy — thinning of the cervical cord on MRI is an early marker of progression, sometimes visible before clear clinical worsening.

Contrast-enhancing lesions — active inflammation with blood-brain-barrier breakdown. Their presence during DMT therapy raises the question of treatment efficacy.

EDSS and the progression threshold

The Expanded Disability Status Scale (EDSS) is the standard tool for measuring MS disability. Progression is formally defined as a sustained increase of at least 1.0 EDSS point (or 0.5 if baseline is above 5.5) confirmed at 3–6 months. For example: moving from EDSS 3.0 (fully ambulatory, moderate disability) to 4.0 (able to walk unaided but significantly limited) and staying there for 3 months is progression. Try our [EDSS calculator](/edss-kalkulator) to estimate your current level.

The difference between a relapse and progression

This distinction is crucial because the response is different:

Relapse: new symptoms or worsening of old symptoms lasting more than 24 hours, often developing over days, sometimes with fever or infection as a trigger. After a relapse, recovery is possible — partial or complete. Treatment: high-dose corticosteroids, possible plasma exchange.

Progression: gradual worsening over months, without a clear start date, often without inflammation markers. Recovery is limited. Treatment: switch to a more effective DMT, add symptomatic therapies, consider rehabilitation intensity.

Pseudorelapse: temporary worsening due to heat, infection or stress, resolving when the trigger is removed. Not true progression.

Some patients experience both simultaneously — relapses superimposed on a background of progression. This is called active progressive MS and requires the most aggressive management.

When to contact your neurologist urgently

Not every change means progression, but the following patterns warrant prompt evaluation:

Contact within days: sudden inability to walk, new paralysis, sudden vision loss in one eye, loss of bladder control with back pain, severe confusion.

Contact within 1–2 weeks: clear step-change in walking distance over 2–4 weeks, new weakness without infection, rapidly worsening spasticity, new cognitive deficits that affect safety (forgetting to turn off stove).

Contact at next scheduled visit: gradual decline over 3–6 months, mild increase in fatigue, subtle balance issues, new numbness that is stable.

Bring a symptom diary to every appointment. Note dates, severity (1–10), triggers, and how symptoms affect daily tasks. This is more valuable than memory alone.

What can slow progression

While MS cannot yet be cured, progression can often be slowed:

1) Switching to a high-efficacy DMT. If new lesions or relapses continue on your current therapy, neurologists increasingly recommend early escalation to ocrelizumab, ofatumumab, natalizumab or rituximab. The principle: "Time is brain" — preventing new lesions preserves function.

2) Treating MS as early as possible. Studies show that starting high-efficacy DMT early reduces long-term disability more than stepwise escalation.

3) Aggressive symptom management. Untreated spasticity, pain, fatigue and depression accelerate disability because they reduce activity, which reduces neuroplasticity. Address every symptom.

4) Rehabilitation and exercise. Regular physiotherapy, resistance training and aerobic exercise (adapted to EDSS level) preserve strength, balance and cardiovascular fitness. Counterintuitively, exercise slows progression markers in some studies (Pilutti 2013, Motl 2017). More: [exercises for MS by EDSS](/blog/joga-multipla-skleroza-edss-nivoi).

5) Vitamin D optimisation. Maintaining serum 25(OH)D above 75–100 nmol/L (30–40 ng/mL) is associated with lower relapse rates and slower progression in observational studies. More: [vitamin D and MS](/blog/vitamin-d-ms-nauka).

6) Lifestyle factors. No smoking, healthy weight, good sleep, stress management and cooling strategies (for heat sensitivity). Every factor that reduces systemic inflammation helps.

7) Clinical trials. For rapidly progressive disease, consider enrolment in trials for remyelination therapies, neuroprotective agents or stem-cell approaches. More: [clinical trials for MS](/blog/klinicke-studije-multipla-skleroza-srbija).

What NOT to do

Do not ignore gradual changes. MS progression is often silent for months, then suddenly visible. Early intervention preserves function.

Do not self-adjust DMT doses. Stopping or skipping infusions because you "feel stable" is one of the most common causes of rebound disease activity.

Do not wait for the annual MRI. If symptoms change significantly, request an earlier scan and an unscheduled neurologist visit.

Do not accept "it is just ageing." While ageing compounds MS, most decline under age 60 in MS is disease-related and treatable.

Progression in MS is not inevitable, and it is not untreatable. The key is early recognition: tracking walking distance, cognitive function, bladder control and fatigue over time; monitoring MRI for new lesions and atrophy; and maintaining open communication with your neurologist. If your current DMT is not controlling the disease, escalation is justified and often effective. Rehabilitation, exercise, vitamin D and lifestyle adjustments add incremental but meaningful protection. The goal is not perfection — it is preserving the maximum possible function for the longest possible time. More: [DMT medications for MS](/blog/dmt-lekovi-multipla-skleroza-2026), [EDSS calculator](/edss-kalkulator), [MS glossary](/blog/ms-recnik-medicinski-termini-multipla-skleroza).

Sources

Lublin FD, et al. "Defining the clinical course of multiple sclerosis: the 2013 revisions." Neurology. 2014: https://pubmed.ncbi.nlm.nih.gov/25371690/. Kappos L, et al. "Long-term effect of early versus delayed interferon beta-1b treatment." J Neurol. 2007: https://pubmed.ncbi.nlm.nih.gov/17503050/. Brown J, et al. "Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis." JAMA. 2019: https://pubmed.ncbi.nlm.nih.gov/30835347/. Motl RW, et al. "Exercise in patients with multiple sclerosis." Lancet Neurol. 2017: https://pubmed.ncbi.nlm.nih.gov/28159273/. Pilutti LA, et al. "Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis." Psychosom Med. 2013: https://pubmed.ncbi.nlm.nih.gov/23788693/. MS Trust — "Progressive MS": https://mstrust.org.uk/a-z/progressive-ms. National MS Society — "Secondary Progressive MS": https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS. This article is informational and does not replace consultation with a neurologist.